Clopidogrel TAD

Company: Clonmel Healthcare Ltd.
Legal category: Prescription. GMS. Sport permitted.
Active ingredient: Clopidogrel (HCl) 75mg.
Description: Pink, round and slightly convex film-coated tablets.
Presentation: 28, €33.58.
Indications: Prevention of atherothrombotic events in adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.

Pharmacology: Clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor, and the subsequent ADP-mediated activation of the GPIIb/IIIa complex, thereby inhibiting platelet aggregation. Biotransformation of clopidogrel is necessary to produce inhibition of platelet aggregation. Clopidogrel also inhibits platelet aggregation induced by other agonists by blocking the amplification of platelet activation by released ADP. Clopidogrel acts by irreversibly modifying the platelet ADP receptor. Consequently, platelets exposed to clopidogrel are affected for the remainder of their lifespan and recovery of normal platelet function occurs at a rate consistent with platelet turnover.
Dosage: Adult: Single daily dose of 75mg with or without food. Children: Safety and efficacy not established.
Contraindications: Hypersensitivity to the active substance or to any of the excipients. Severe liver impairment. Active pathological bleeding such as peptic ulcer or intracranial haemorrhage. Pregnancy, lactation (precautionary measure).
Special precautions: Not recommended during the 1st 7 days after acute ischaemic stroke. Caution: Patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions or treatment, including lesions with a propensity to bleed (particularly gastrointestinal and intraocular); renal impairment, patients with moderate hepatic disease who may have bleeding diatheses. Discontinue 7 days prior to surgery. Consider blood cell count determination and/or other appropriate testing if clinical symptoms suggestive of bleeding arise during treatment. Thrombotic Thrombocytopenic Purpura (TTP) reported very rarely. Contains hydrogenated castor oil.
Drug interactions: Not recommended: Anticoagulants. Caution: ASA, heparin, thrombolytics, glycoprotein IIb/IIIa inhibitors, NSAIDs.
Adverse drug reactions: Haematoma, epistaxis, GI disorders, bruising, bleeding at puncture site.
Full prescribing information and references available from Clonmel Healthcare Ltd. Telephone (052) 6177777. Fax: (052) 6177791. E-mail: medicalinformation@clonmel-health.ie